1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
The administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (1-4 mg/kg i.p.) for 4 days induced dose-dependent parkinsonism in the common marmoset within 48 h. MPTP produced profound akinesia, rigidity of the trunk and limbs, postural abnormalities, loss of vocalization and, in some cases, postural tremor. In a single animal the administration of L-DOPA in conjunction with a peripheral decarboxylase inhibitor, reversed the parkinsonian symptoms. Subsequent biochemical analysis showed a profound loss of dopamine and [3H]dopamine uptake in the caudate-putamen, but no change in specific [3H]spiperone binding.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015102:3,4-Dihydroxyphenylacetic Acid / Q000032:analysis; D000818:Animals; D002143:Callitrichinae; D002421:Caudate Nucleus / Q000032:analysis; D004298:Dopamine / Q000032:analysis; D005260:Female; D006719:Homovanillic Acid / Q000032:analysis; D007980:Levodopa / Q000627:therapeutic use; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000378:metabolism; D011699:Putamen / Q000032:analysis; D011725:Pyridines / Q000494:pharmacology*
D011725:Pyridines; D015102:3,4-Dihydroxyphenylacetic Acid; D007980:Levodopa; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine; D006719:Homovanillic Acid